Asset Details
Do you wish to reserve the book?
Hydrofluoroalkane-134a Beclomethasone Dipropionate, 400 μg, Is as Effective as Chlorofluorocarbon Beclomethasone Dipropionate, 800 μg, for the Treatment of Moderate Asthma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Hydrofluoroalkane-134a Beclomethasone Dipropionate, 400 μg, Is as Effective as Chlorofluorocarbon Beclomethasone Dipropionate, 800 μg, for the Treatment of Moderate Asthma
Do you wish to request the book?
Hydrofluoroalkane-134a Beclomethasone Dipropionate, 400 μg, Is as Effective as Chlorofluorocarbon Beclomethasone Dipropionate, 800 μg, for the Treatment of Moderate Asthma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Hydrofluoroalkane-134a Beclomethasone Dipropionate, 400 μg, Is as Effective as Chlorofluorocarbon Beclomethasone Dipropionate, 800 μg, for the Treatment of Moderate Asthma
1999
Overview
The improved lung deposition of hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP) extrafine aerosol compared with chlorofluorocarbon beclomethasone dipropionate (CFC-BDP) suggests that lower doses of HFA-BDP may be required to provide equivalent asthma control. The present study was undertaken to test this hypothesis.
A 10- to 12-day run-in period confirmed that patients met established criteria of at least moderate asthma and the asthma was inadequately controlled by current therapy (inhaled β-agonist and CFC-BDP [≤ 400 μg/d]). A short course of oral prednisone, 30 mg/d for 7 to 12 days, was followed to establish the patients were steroid responsive and to provide an“ in-study” baseline of “optimal” asthma control.
A total of 347 patients were then randomized to HFA-BDP 400 μg/d, CFC-BDP 800 μg/d, or HFA-placebo for 12 weeks.
Morning peak expiratory flow (am PEF) measurements showed that HFA-BDP 400 μg/d achieved equivalent control of asthma to CFC-BDP 800 μg/d at all time intervals after oral steroid treatment. All other efficacy variables supported the am PEF results and both active treatments were more effective than placebo. The safety profile of HFA-BDP compared favorably with that of CFC-BDP with no unexpected adverse events reported.
These findings demonstrate that HFA-BDP provides equivalent control of moderate or moderately severe asthma as CFC-BDP in the population studied, but at half the total daily dose.
Publisher
Elsevier Inc,American College of Chest Physicians
